Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

98 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-15

Study Completion Date

2025-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach. The device studied, EmoDTx, is a mood-monitoring application that analyzes patients' facial expressions to assess their emotional state. The study aims to compare mood scores obtained via EmoDTx with those of standard depression questionnaires (MADRS, PHQ-9, BDI-II, HAMD-17, QIDS-SR16). It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of the patient) and how the feedback sent to patients can help in their care.

Participants who agree to take part in the study, during a selection visit, will be able to:

1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 8-week follow-up period.
2. Attend scheduled appointments at the center (a first appointment, then a second 4 weeks later, and a final at 8 weeks) to complete a series of questionnaires, be questioned by the doctor, and fill in other questionnaires on their own.
3. At home, answer questionnaires independently, 2 weeks and 6 weeks after the first appointment.
4. The application's feedback will be deactivated during the first 4 weeks and then reactivated during the final 4 weeks.
5. In parallel, an ancillary study will be conducted on 16 patients enrolled in EMC2FR who accepted and performed the video recording of their structured clinical interview following SCID-5-CV at baseline and 4 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode

NCT06601140

Major Depressive Disorder (MDD)

RECRUITING NA

Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology

NCT03067506

Major Depressive Disorder

COMPLETED

Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders

NCT05547035

Major Depressive Disorder

RECRUITING NA

Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study

NCT06732089

Major Depressive Disorder (MDD) Major Depressive Episode Treatment-Resistant Major Depressive Disorder

RECRUITING

Digital Phenotypes for Predicting Depression

NCT07151846

Depression - Major Depressive Disorder Depression Bipolar Bipolar Disorder (BD) +1 more

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unipolar Depression Major Depressive Disorder (MDD) Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Outpatients diagnosed with mild to severe unipolar disorder
2. Age ≥ 18 years old
3. Patients willing and able to participate (i.e willing to use the EmoDTx App and having the necessary technical equipment to use it)
4. Patients who read, write and understand French
5. Patients having signed the Patient Informed Consent

Exclusion Criteria

1. Patients hospitalized
2. Patients taking more than 75% of the maximal recommended daily dose of benzodiazepines
3. Patients taking more than 75% of the maximal recommended daily dose of antipsychotics
4. Patients taking more than 75% of the maximal recommended daily dose of neuroleptics
5. Patients who did not respond to 10 different pharmacological treatments
6. Patients who attempted suicide within the previous last 6 months and presenting with suicidal ideations
7. Patient presenting with bipolar disorders
8. Patients with a contra-indication to the device under evaluation:

* Severe depression requiring hospitalization
* Schizophrenic disorders according to DSM 5 classification
* Major neurocognitive disorders according to DSM 5 classification
* Illiteracy
* Subject hospitalized in a healthcare or social institution for reasons other than biomedical research or is deprived of freedom by administrative or judicial decision or is placed under guardianship
9. Patients unable to read, write and understand French
10. Patients with no access to a smartphone or a computer with an internet connection
11. Patients who refuse to sign the Patient Informed Consent
12. Patients already participating in another interventional clinical study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No